<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199667</url>
  </required_header>
  <id_info>
    <org_study_id>I02013</org_study_id>
    <nct_id>NCT00199667</nct_id>
  </id_info>
  <brief_title>Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients</brief_title>
  <official_title>APOMYGRE : Multicenter, Randomized, Open-Label Study of MMF Therapeutic Follow-up's Interest in the the 12 First Months in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      Acumulating data suggest that thrapeutic drug therapeutic may optimize efficacity and
      tolerance of MMF. It could guarantee better exposure to the drug in the first 3 months and
      then minimize side effects in the long term. However definitive proof is still lacking. We
      conducted a randomized study in 11 french centers and included 137 kidney transplant
      recipients (PRA&lt;50%) receiving a classical immunosuppressant regimen with basiliximab, Csa,
      MMF and steroids. The &quot;fixed dose&quot; group received 2 g of MMF a day. The &quot;concentration
      controlled&quot; group received MMF dose adapted to the area under the concentration curve (AUC)
      of MPA, with a target of 40 h.mg/L. After transplantation AUCs were calculated with a
      Bayesian estimator using a 3-point limited sampling strategy on day 7, 14, and months 1, 3, 6
      , 12 in both groups (values note communicated to the physicians in the &quot;fixed dose&quot; group.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2002</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunosuppressant treatment fealure (kidney rejection, adverse events, death, graft lost).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal fonction evolution</measure>
  </secondary_outcome>
  <enrollment>137</enrollment>
  <condition>Kidney Transplant Recipients</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients received a first or a second kidney transplantation

          -  patients with panel reactive antibody &lt;or= 50 %

          -  patients with cellcept treatment since fewer 3 days

          -  patients receiving or being received ciclosporine treatment

          -  patients without retention, important hepatic cytolysis

          -  patients without post-surgical complication or intercurrent disease

          -  informed consent signed

        Exclusion Criteria:

          -  patients included in other study

          -  patients with MMF or mycophenolic acid hypersensibility or MMF contraindication

          -  patients with gastroduodenal disorder before the beginning of the study

          -  pregnant women or without contraception

          -  patients with rapamycin or analogous

          -  patients with toxicomania or psychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yann LE MEUR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 14, 2008</last_update_submitted>
  <last_update_submitted_qc>December 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2008</last_update_posted>
  <keyword>MMF, Monitoring, area under curve (AUC), kidney transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

